Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. It operates in the United States, Australia, Canada, Israel, Brazil, Russia, and Turkey. The company is headquartered in Hackensack. New Jersey.
Metrics to compare | PLX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPLXPeersSector | |
---|---|---|---|---|
P/E Ratio | 20.3x | −2.4x | −0.5x | |
PEG Ratio | 0.15 | −0.14 | 0.00 | |
Price/Book | 2.5x | 2.5x | 2.6x | |
Price / LTM Sales | 2.1x | 8.2x | 3.3x | |
Upside (Analyst Target) | - | 171.9% | 38.7% | |
Fair Value Upside | Unlock | 3.0% | 5.0% | Unlock |